BioNexus Gene Lab Corp.
BGLC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $9 | $164 | $365 |
| - Cash | $4 | $6 | $2 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $3 | $162 | $363 |
| Revenue | $10 | $10 | $11 | $13 |
| % Growth | -2.7% | -10.6% | -18.2% | – |
| Gross Profit | $1 | $1 | $1 | $2 |
| % Margin | 13.6% | 13.6% | 11.5% | 16.4% |
| EBITDA | -$1 | -$2 | -$0 | $1 |
| % Margin | -14.9% | -25.4% | -1.7% | 8.7% |
| Net Income | -$2 | -$3 | -$0 | $1 |
| % Margin | -16.8% | -26.9% | -3.3% | 5.6% |
| EPS Diluted | -0.9 | -1.53 | -0.25 | 0.53 |
| % Growth | 41.2% | -512% | -147.2% | – |
| Operating Cash Flow | -$2 | -$2 | $1 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$2 | $0 | $0 |